Kai Romero, MD1,2; Eric Widera, MD3,4; Melissa W. Wachterman, MD, MSc, MPH5,6,7
doi : 10.1001/jamainternmed.2022.6390
March 2023, Vol 183, No. 3, Pages 176-278
Michael A. Incze, MD, MSEd1,2
Thomas Heisser, MSc1,2; Jens Kretschmann, MSc3; Bernd Hagen, PhD3; Tobias Niedermaier, PhD1; Michael Hoffmeister, PhD1; Hermann Brenner, MD1,4,5
doi : 10.1001/jamainternmed.2022.6215
Importance Screening colonoscopy to prevent and early detect colorectal cancer is recommended to be repeated in 10-year intervals, which goes along with high demands of capacities and costs. Evidence of findings at screening colonoscopies conducted 10 or more years after a negative colonoscopy result is sparse, and it remains unclear whether screening colonoscopy intervals could possibly be prolonged.
Nauzer Forbes, MD, MSc1,2; B. Joseph Elmunzer, MD, MSc3; Thibault Allain, PhD4; Michael D. Parkins, MD, MSc5,6; Prameet M. Sheth, PhD7,8; Barbara J. Waddell, BSc5; Kristine Du, BSc5; Katya Douchant, MSc7; Olajumoke Oladipo, MSc9; April Saleem, BSc8; Shane Cartwright, BSc1; Millie Chau, BSc1; Megan Howarth, BSc1; Jackie McKay, BSc11; Tamim Nashad, MD1; Yibing Ruan, PhD, MPH10,11; Kirles Bishay, MD, MSc1; Emmanuel Gonzalez-Moreno, MD1; Zhao Wu Meng, BMBS1; Sydney Bass, MD1; Robert Bechara, MD12; Martin J. Cole, MD1; Diederick W. Jalink, MD13; Rachid Mohamed, MD1; Christian Turbide, MD1; Paul J. Belletrutti, MD1; Ahmed Kayal, MD, MSc1; Puja R. Kumar, MD1; Robert J. Hilsden, MD, PhD1,2; André G. Buret, PhD4; Lawrence Hookey, MD12; Steven J. Heitman, MD, MSc1,2
doi : 10.1001/jamainternmed.2022.6394
Importance Infection transmission following endoscopic retrograde cholangiopancreatography (ERCP) can occur due to persistent contamination of duodenoscopes despite high-level disinfection to completely eliminate microorganisms on the instrument.
Luke P. Dawson, MBBS, MPH1,2,3; Emily Nehme, MBiostats2,4; Ziad Nehme, PhD2,4,5; Ella Zomer, PhD2; Jason Bloom, MBBS1,6; Shelley Cox, PhD2,4; David Anderson, MBChB4,5,7; Michael Stephenson, BHlthSci, GradDipHlthSci2,4,5; Jocasta Ball, PhD2; Jennifer Zhou, MBBS1; Jeffrey Lefkovits, MBBS2,3; Andrew J. Taylor, MBBS, PhD1,8; Mark Horrigan, MBBS9,10; Derek P. Chew, MBBS, MPH, PhD11; David Kaye, MBBS, PhD1,6; Louise Cullen, MBBS, PhD12; Cathrine Mihalopoulos, PhD2; Karen Smith, PhD2,4,5; Dion Stub, MBBS, PhD1,2,6
doi : 10.1001/jamainternmed.2022.6409
Importance Prehospital point-of-care troponin testing and paramedic risk stratification might improve the efficiency of chest pain care pathways compared with existing processes with equivalent health outcomes, but the association with health care costs is unclear.
Soheila Aghlmandi, PhD1; Florian S. Halbeisen, PhD1; Ramon Saccilotto, MD2; Pascal Godet3; Andri Signorell4; Simon Sigrist5; Dominik Glinz, PhD1; Giusi Moffa, PhD6; Andreas Zeller, MD7; Andreas F. Widmer, MD, MSc8; Andreas Kronenberg, MD9; Julia Bielicki, MD, PhD10,11; Heiner C. Bucher, MD, MPH1
doi : 10.1001/jamainternmed.2022.6529
Importance Antibiotics are commonly prescribed in primary care, increasing the risk of antimicrobial resistance in the population.
Eduard E. Vasilevskis, MD, MPH1,2,3,4; Avantika Saraf Shah, MPH1; Emily Kay Hollingsworth, MSW1; Matthew Stephen Shotwell, PhD5; Sunil Kripalani, MD, MSc1,3,4; Amanda S. Mixon, MD, MS, MSPH1,2,3,4; Sandra F. Simmons, PhD1,2,4,6
doi : 10.1001/jamainternmed.2022.6545
Importance Deprescribing is a promising approach to addressing the burden of polypharmacy. Few studies have initiated comprehensive deprescribing in the hospital setting among older patients requiring ongoing care in a postacute care (PAC) facility.
Siwen Wang, MD1; Yanping Li, PhD1; Yiyang Yue, MS1; Changzheng Yuan, ScD1,2; Jae Hee Kang, ScD3; Jorge E. Chavarro, MD, ScD1,3,4; Shilpa N. Bhupathiraju, PhD1,3; Andrea L. Roberts, PhD5
doi : 10.1001/jamainternmed.2022.6555
Importance Few modifiable risk factors for post–COVID-19 condition (PCC) have been identified.
Elvira D’Andrea, MD, PhD1; Deborah J. Wexler, MD, MSc2; Seoyoung C. Kim, MD, ScD1; Julie M. Paik, MD, ScD, MPH1,3,4; Ethan Alt, PhD1; Elisabetta Patorno, MD, DrPH1
doi : 10.1001/jamainternmed.2022.6664
Importance Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy has been associated with cardiovascular benefits and a few adverse events; however, whether the comparative effectiveness and safety profiles vary with differences in baseline hemoglobin A1c (HbA1c) levels is unknown.
Isabel R. Ostrer, MD1; Tracy Y. Wang, MD, MHS, MSc2,3
Melinda Wang, MD1; Graham M. Snyder, MD, SM2,3
Jeffrey A. Linder, MD, MPH1; Craig R. Fox, PhD2
Vanessa Northington Gamble, MD, PhD1
Elizabeth M. Viglianti, MD, MPH, MSc1; Lisa M. Meeks, PhD2; Andrea L. Oliverio, MD, MSc3; Kathleen Tiffany Lee, MPH1; Theodore J. Iwashyna, MD, PhD4; Susan T. Hingle, MD5
Rachel E. Warren, BA1; Sanket S. Dhruva, MD, MHS2,3,4; Madris Kinard, MBA5; John M. Neuhaus, PhD4,6; Rita F. Redberg, MD2,3,4,7
Ying Chen, MD, PhD1; Zheng Chen, MD2; Lingling Pan, MD, PhD3; Zhi-Min Ma, MD, PhD4; Huijie Zhang, MD, PhD5; Xue-Jun Li, MD, PhD2; Xiaoying Li, MD, PhD1,6
Junyi Wang, MS1; ChangWon C. Lee, AB1; Aaron S. Kesselheim, MD, JD, MPH1; Benjamin N. Rome, MD, MPH1
Michael Brouner, MD1; Jamey Hammock, MD2; Harish Doppalapudi, MD3
Ruihai Zhou, MSc, MD, RPVI1
Zhangli Yang, MD1; Chuan-Hai Zhang, MD2; Xuanxuan Li, MD3
Jun-Peng Liu, MD, PhD1; Wen-Duo Zhang, MD, PhD1; Hua Wang, MD1
Christophe Vandenbriele, MD, PhD1; Guido Tavazzi, MD, PhD2; Susanna Price, MD, PhD3
P. Elliott Miller, MD, MHS1; Nihar R. Desai, MD, MPH1
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟